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Endothelial Dicer promotes atherosclerosis and
vascular inflammation by miRNA-103-mediated
suppression of KLF4
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MicroRNAs regulate the maladaptation of endothelial cells (ECs) to naturally occurring
disturbed blood flow at arterial bifurcations resulting in arterial inflammation and
atherosclerosis in response to hyperlipidemic stress. Here, we show that reduced endothelial
expression of the RNAse Dicer, which generates almost all mature miRNAs, decreases
monocyte adhesion, endothelial C–X–C motif chemokine 1 (CXCL1) expression, athero-
sclerosis and the lesional macrophage content in apolipoprotein E knockout mice (Apoe–/–)
after exposure to a high-fat diet. Endothelial Dicer deficiency reduces the expression of
unstable miRNAs, such as miR-103, and promotes Krüppel-like factor 4 (KLF4)-dependent
gene expression in murine atherosclerotic arteries. MiR-103 mediated suppression of KLF4
increases monocyte adhesion to ECs by enhancing nuclear factor-kB-dependent CXCL1
expression. Inhibiting the interaction between miR-103 and KLF4 reduces atherosclerosis,
lesional macrophage accumulation and endothelial CXCL1 expression. Overall, our study
suggests that Dicer promotes endothelial maladaptation and atherosclerosis in part by miR-
103-mediated suppression of KLF4.
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E
ndothelial cells (ECs) are perfectly adapted to conduct blood
through high-shear stress, high-pressure environment in
unbranched segments of arteries1. High-shear stress at the
endothelial surface induces the transcription factors Krüppel-like
factors (KLF) 2 and KLF4, which promote a quiescent EC
phenotype characterized by a low turnover rate, tight intercellular
junctions with low permeability, reduced inflammatory activation
and antithrombotic properties2–4. However, distribution of blood
throughout the body requires branching of arteries where blood
flow is naturally disturbed and consequently shear stress is low5.
Disturbed flow at arterial bifurcations constantly damages the
endothelium by activating the endoplasmic reticulum stress
response, suppresses EC-specific transcriptional programmes by
downregulating KLF2/4, and increases the activity of
the proinflammatory transcription factor nuclear factor-kB
(NF-kB)6–8. Moreover, the deposition of chemically modified
lipoproteins in the subendothelial space aggravates the
maladaptive response of ECs and results in the accumulation of
macrophages derived from circulating monocytes in the arterial
wall during atherosclerosis9–11. Inflammatory activation of
macrophages triggers the secretion of inflammatory cytokines,
such as tumour necrosis factor-a (TNF-a) and interleukin-1,
which further promotes endothelial maladaptation by activating
NF-kB12,13. Endothelial chemokines, such as chemokine (C–X–C
motif) ligand 1 (CXCL1), chemokine (C–C motif) ligand 2
(CCL2) and chemokine (C–X3–C) ligand 1 (CX3CL1), have key
roles in the accumulation of macrophages in atherosclerotic
lesions14–17. ECs secrete CXCL1 and CCL2 from intracellular
storage compartments upon activation by thrombin or
lipoprotein oxidation products15,18. Whereas CXCL1 is
immobilized on the endothelial surface and triggers monocyte
adhesion by activating integrins on the monocyte surface15,19,
CCL2 contributes to macrophage infiltration probably by
regulating hypercholesterolemia-induced monocytosis17,20. The
membrane-bound chemokine CX3CL1 is upregulated in inflamed
ECs and promotes atherogenic monocyte adhesion by activating
platelets21. Constitutive and induced expression of CXCL1, CCL2
and CX3CL1 are controlled by the activity of NF-kB22,23.
MicroRNAs (miRNAs) are small noncoding RNAs of B22
nucleotides that regulate a number of processes related to
atherogenesis, such as macrophage activation and the phenotype
of vascular smooth muscle cells (SMCs), by translational
repression or degradation of their target mRNAs24–26. Mature
miRNA sequences are embedded in the stem-loop structure of
their primary miRNA (pri-miRNA) transcripts. The nuclear
RNAse III Drosha crops the pri-miRNA stem at the 50 and 30
sides to release a B65-nucleotide-long, hairpin-shaped precursor
miRNA (pre-miRNA). In the cytoplasm, the RNAse III
endonuclease Dicer cleaves all pre-miRNAs, except pre-miR-
451, near the terminal loop of the hairpin into 21 to 25-
nucleotide-long miRNA duplexes, which are subsequently loaded
onto Argonaut proteins27. Although one strand of the miRNA
duplex is selected during the loading step to generate the RNA-
induced silencing complex (RISC), the second strand is usually
removed and degraded. Binding to Argonaut proteins protects
miRNAs from degradation by exonucleases and thus greatly
increases their stability compared with that of mRNAs. However,
the expression level of a small subset of miRNAs is highly
dependent on continuous biogenesis because of a fast turnover
rate28,29.
Deletion of the gene encoding Dicer in mice compromises
blood vessel formation and causes embryonic lethality, indicating
an essential role of this endonuclease in vertebrate develop-
ment30,31. In adults, Dicer is essential for the function of various
cell types, such as pancreatic beta cells and cardiomyocytes32,33,
and reduced Dicer expression contributes to aging and promotes
cancer development34,35. Although deletion of Dicer in SMCs
results in embryonic lethality36, mice with deficiency of Dicer in
ECs develop normally and have no overt phenotype37. However,
reduced endothelial Dicer expression severely impairs postnatal
angiogenesis and limits the proliferation and migration of
ECs37–39. Notably, knockdown of Dicer induces upregulation of
EC-specific genes, such as endothelial nitric oxide synthase
(eNOS), Angiopoietin-1 receptor (Tie2) and vascular endothelial
growth factor receptor 2 (KDR), indicating that Dicer generates
miRNAs that impair endothelial differentiation38. Disturbed
blood flow increases the expression of several endothelial
miRNAs, including miR-92a and miR-712, which promote
atherosclerosis by targeting KLF2/4 and by increasing shedding
of membrane-bound TNF-a, respectively7,40,41. Moreover, several
miRNAs have been implicated in NF-kB pathway regulation in
ECs. For example, miR-10a, miR-146a and miR-181b promote an
anti-inflammatory phenotype in ECs by inhibiting the NF-kB
pathway, whereas miR-19a has a proinflammatory role in
ECs42–45. Although individual miRNAs affect endothelial
inflammation, it is unclear which role Dicer-dependent miRNA
biogenesis in ECs plays in atherosclerosis.
Here, we investigated the role of endothelial Dicer in monocyte
adhesion and atherosclerosis. EC-specific deletion of Dicer in
apolipoprotein E-knockout (Apoe–/–) mice reduced monocyte
adhesion to the early atherosclerotic endothelium by down-
regulating CXCL1, resulting in diminished lesion formation.
MiR-103 is downregulated in Dicer-deficient ECs and promoted
CXCL1-mediated monocyte adhesion by targeting KLF4. Block-
ing the interaction between miR-103 and KLF4 in arteries
reduced atherosclerosis, lesional macrophage accumulation and
CXCL1 expression, similar as the deletion of Dicer in ECs.
Overall, these data indicate that Dicer can enhance atherosclerosis
and endothelial inflammation by increasing miR-103 expression.
Results
Endothelial Dicer regulates miRNAs during atherosclerosis.
Although many miRNAs are downregulated in atherosclerotic
arteries26, Dicer expression in the aortas of Apoe–/– mice was not
affected by 12 weeks of high-fat diet (HFD) feeding compared
with mice fed a normal diet (Supplementary Fig. 1a), indicating
that miRNA biogenesis by Dicer is not generally impaired during
early atherosclerosis. Moreover, the expression of Dicer in ECs
was not affected by low-shear stress and did not differ between
the aortic arch and thoracic aorta, indicating that Dicer is not
regulated by blood flow (Supplementary Fig. 1b,c). To study the
role of endothelial Dicer in atherosclerosis, we generated Apoe–/–
mice containing a loxP site-flanked Dicer sequence (Dicerflox) and
a transgene with Tamoxifen (TMX) inducible Cre recombinase
under control of the EC-specific VE-cadherin (Cdh5) promoter.
TMX administration reduced aortic Dicer mRNA expression in
EC-Dicerflox mice by 66% and 58% compared with EC-DicerWT
mice after 4 and 12 weeks of HFD feeding, respectively (Fig. 1a).
In ECs isolated from the aortas of EC-Dicerflox mice injected with
TMX, Dicer mRNA expression was decreased by 87% compared
with ECs isolated from EC-DicerWT mice (Fig. 1b), whereas the
expression of Dicer was not affected in myeloid cells from
EC-Dicerflox mice (Supplementary Fig. 1d). These results indicate
that TMX treatment of EC-Dicerflox mice effectively reduced
Dicer expression in ECs.
To determine the effect of endothelial Dicer deficiency on
miRNA biogenesis during atherosclerosis, the miRNA expression
profile was determined in aortas from HFD-fed EC-Dicerflox and
EC-DicerWT mice by quantitative real-time PCR (qRT–PCR)
arrays. After 4 weeks of HFD feeding, 14 miRNAs were
downregulated and 9 miRNAs were upregulated in EC-Dicerflox
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mice compared with EC-DicerWT mice (Fig. 1c and
Supplementary Table 1). After 12 weeks of HFD exposure, 18
miRNAs and 8 miRNAs were down- and upregulated in
EC-Dicerflox mice, respectively (Fig. 1d and Supplementary
Table 2). Notably, the expression levels of miR-103, miR-301b,
miR-433 and miR-652 were downregulated in EC-Dicerflox mice
at the 4- and 12-week time points. In contrast to miR-301b,
endothelial Dicer deficiency reduced the expression levels of
miR-103, miR-433 and miR-652 in both aortic arch and thoracic
aorta (Supplementary Fig. 2), indicating that the effect of
endothelial Dicer on these miRNAs is independent of disturbed
flow. Moreover, the expression levels of miR-103, miR-652 and
miR-301b in EC-DicerWT mice were higher at the 12-week time































































































































































































Figure 1 | Effect of endothelial Dicer on miRNA expression during atherosclerosis. (a) Quantitative RT–PCR analyses of Dicer mRNA expression in the
aortas from TMX-treated EC-DicerWT and EC-Dicerflox mice fed a HFD for 4 or 12 weeks (wks; n¼ 5 mice per group). (b) Dicer mRNA expression levels in
aortic ECs isolated from EC-DicerWT and EC-Dicerflox mice 2 weeks after TMX injection (n¼ 3 per group). (c,d) Differentially expressed miRNAs (grey
areas) in the aortas of EC-Dicerflox mice compared with EC-DicerWT mice (n¼ 3 mice per group) after exposure to a HFD for 4 (c) or 12 weeks (d). The
expression profiles were determined using qRT–PCR arrays. RQ, relative quantification. (e) The expression levels of miR-103, miR-301b, miR-433 and miR-
652 in the aortas of EC-DicerWT mice fed a HFD for 4 or 12 weeks (n¼ 3 mice per group). (f) Quantitative RT–PCR analyses of miR-103, miR-301b, miR-
433, miR-652 and miR-126-3p expression in human aortic ECs (HAECs) treated with Dicer-specific LNA-GapmeRs or non-targeting control LNA-GapmeRs
(n¼ 3–4 per group). The data are represented as the mean±s.e.m. of the indicated number (n) of repeats. *Po0.05; **Po0.01 and ***Po0.001 by
Student’s t-test.
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(HAECs), silencing of Dicer using GapmeRs diminished the
expression levels of miR-103, -301b, -652 and -433, but not that
of miR-126-3p, after 24 h (Fig. 1f and Supplementary Fig. 3). In
summary, these results suggest that endothelial Dicer deficiency
selectively lowers the expression levels of unstable miRNAs, most
of which are upregulated during atherosclerosis.
Endothelial Dicer promotes atherosclerosis. To determine the
role of Dicer in endothelial inflammation, monocytic cell arrest
was studied ex vivo using perfused carotid arteries from
EC-Dicerflox and EC-DicerWT mice that were fed a HFD for 4
weeks. Monocyte adhesion (Fig. 2a) and the expression levels of
the Cxcl1, Cx3cl1 and Ccl2 mRNAs (Fig. 2b) were significantly
lower in carotid arteries from EC-Dicerflox mice than in those
from EC-DicerWT mice. Reduced endothelial expression of
CXCL1 in EC-Dicerflox mice was identified by dual immunos-
taining of CXCL1 and the endothelial marker CD31 (Fig. 2c).
These results suggest that endothelial Dicer enhances chemokine
expression and may promote monocyte adhesion during the early
stages of atherosclerosis. After 12 weeks of HFD feeding, ather-
osclerosis in the aortic roots (Fig. 3a) and thoracoabdominal
aortas (Fig. 3b) of EC-Dicerflox mice was 58% and 41% lower than
that in EC-DicerWT mice, respectively. The distribution of
atherosclerotic lesions in the aorta did not differ between EC-
Dicerflox and EC-DicerWT mice (Supplementary Fig. 4). The
number of macrophages per lesion (Fig. 3c) and the SMC content
(Fig. 3d) were diminished in EC-Dicerflox mice. Deletion of the
endothelial Dicer gene did not affect serum cholesterol levels
(Supplementary Fig. 5). Taken together, these findings indicate
that the expression of Dicer in ECs enhances atherosclerotic
lesion formation.
miR-103 induces endothelial inflammation. Among the
miRNAs downregulated in the aorta of EC-Dicerflox mice,
miR-103 was expressed most abundantly in human ECs (Fig. 4a)
and was highly enriched in the RISCs of these cells, as determined
using anti-argonaute 2 (AGO2)-immunoprecipitation, suggesting
a prominent role for miR-103 in the regulation of EC function
(Fig. 4b). Notably, the expression of miR-107, which shares the
same seed sequence with miR-103, was not affected by
endothelial Dicer deletion (Fig. 1c,d and Supplementary Tables 1
and 2). Stimulation of HAECs with TNF-a moderately induced
miR-103 and suppressed miR-433 expression, whereas blocking
of NF-kB reduced only the expression of miR-103 and -301b
(Fig. 4c,d). In addition, the expression of miR-103 was
upregulated in HAECs upon stimulation with native low-density
lipoprotein (LDL) and further increased by mildly oxidized LDL
treatment (Fig. 4e). These data suggest that NF-kB activity and
hyperlipidemia drive the expression of miR-103 in atherosclerotic
ECs, which may in turn indirectly regulate the chemokine
expression.
In addition, miR-103 was highly expressed in the aortic
endothelium after 4 and 12 weeks of HFD feeding in EC-DicerWT
mice, whereas endothelial miR-103 expression was not detectable
by in situ PCR in EC-Dicerflox mice (Fig. 4f and Supplementary
Fig. 6). Similarly, combined in situ PCR and immunostaining of
von Willebrand factor (vWF) revealed prominent miR-103
expression in ECs covering human atherosclerotic lesions (Fig.
4g,h). These results suggest that Dicer-mediated generation of
endothelial miRNAs, in particular miR-103, may play a crucial
role in lesion formation.
Overexpression of miR-103 was sufficient to upregulate the









































































































Figure 2 | Role of endothelial Dicer in atherogenic monocyte adhesion. (a) Ex vivo perfusion assays showing monocytic cell arrest on the endothelia of
the left carotid arteries of mice (n¼4–5 mice per group) fed a HFD for 4 weeks. (b) Quantitative RT–PCR analyses of the mRNA expression levels of
chemokines in carotid arteries of mice (n¼ 3–4 mice per group) fed a HFD for 4 weeks. (c) Immunostaining of CXCL1 and the endothelial marker CD31 in
carotid artery sections after 4 weeks of HFD feeding. Arrows indicate CXCL1 expressing ECs. Representative images of three independent experiments are
shown. The nuclei were stained with 4’,6-diamidino-2-phenylindole (DAPI). Scale bars, 30 mm (a), 12 mm (c). Asterisks indicate the lumen. The data are
represented as the mean±s.e.m. of the indicated number (n) of repeats. *Po0.05 and **Po0.01 by Student’s t-test.
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silencing Dicer in HAECs (Fig. 5a). Furthermore, treatment of
HAECs with a specific locked nucleic acid (LNA)-inhibitor,
which reduced miR-103 expression by 70% (Fig. 5b), also
reduced the expression of the CXCL1, CX3CL1 and CCL2
mRNAs significantly (Fig. 5c). Downregulation of CXCL1 was
also confirmed at the protein level (Fig. 5d). Next, in vitro flow
chamber assays were used to examine the effect of miR-103 on
monocyte adhesion to ECs. Unlike non-targeting LNA-oligo-
nucleotides, LNA-inhibitors of miR-103 attenuated the adhesion
of monocytic cells to HAECs (Fig. 5e). Conversely, transfection
of HAECs with miR-103 mimics, which increased miR-103
expression by 22-fold (Fig. 5f), upregulated the expression levels
of CXCL1 and CX3CL1, but had only a slight effect on the
expression of CCL2 (Fig. 5g). Furthermore, overexpression of
miR-103 in HAECs increased monocytic cell adhesion, and this
effect was reversed by blocking the CXCL1 receptor C–X–C
chemokine receptor type 2 on monocytes (Fig. 5h). These
findings suggest that reduced expression of miR-103 in
EC-Dicerflox mice results in diminished adhesion of monocytes
to the carotid arteries.
Endothelial Dicer regulates KLF4-dependent gene expression.
To study the mechanism by which deficiency of endothelial Dicer
reduced lesion formation, genome-wide microarray analyses of
atherosclerotic arteries from EC-DicerWT and EC-Dicerflox mice
fed a HFD for 12 weeks were performed (n¼ 2 mice per group;
Po0.05 by a moderated t-test (Limma); fold change cutoff¼ 1.2).
Overall, 469 transcripts were upregulated and 652 transcripts
were downregulated in EC-Dicerflox mice compared with EC-
DicerWT mice. In addition to the transcription factor c-Myb, the
Wnt pathway members transcription factor 7 (Tcf7) and lymphoid
enhancer-binding factor 1 (Lef1) and the expression of EC-specific
genes, such as Cadherin 5 (Cdh5; also known as VE-Cadherin),
Claudin-5 (Cldn5), BMX non-receptor tyrosine kinase (Bmx) and
SRY (sex-determining region Y)-box 17 (Sox17), were increased in
EC-Dicerflox mice (Fig. 6a). By contrast, the expression level of
proinflammatory genes, like Ccl2, CD44 antigen (CD44), Rho-
associated coiled-coil containing protein kinase 1 (Rock1) and
Nfkb1, was reduced in the aortas of EC-Dicerflox mice (Fig. 6a).
We confirmed by qRT–PCR in a larger number of mice that
endothelial Dicer deficiency increases the expression level of c-
Myb, Tcf7, dickkopf homolog 2 (Dkk2) and Sox17; however, the
expression of Lef-1 only tended to be increased in EC-Dicerflox
mice (Fig. 6b). Next, we analysed the differentially expressed
genes using Ingenuity Pathway Analysis software. Genes related
to biological processes such as development of blood vessels,
inflammatory response, chemotaxis and immune cell adhesion
were enriched among the differentially expressed genes in EC-
Dicerflox mice (Fig. 6c). Moreover, the expression levels of genes
related to the KLF4 pathway were also differentially expressed in
EC-Dicerflox mice and were indicative of increased KLF4 signal-


















































































































































Figure 3 | Loss of endothelial Dicer limits atherosclerosis. (a,b) Atherosclerotic lesion formation in mice fed a HFD for 12 weeks analysed in aortic root
sections stained with elastic van Gieson stain (a; n¼ 8 mice per group) and in en face prepared aortas stained with Oil red O stain (b; n¼9–10 mice per
group). (c,d) Macrophage and smooth muscle cell accumulation in aortic root lesions determined by immunostaining of MAC2 (c, green; n¼ 7–9 mice per
group) and smooth muscle actin (d, red; n¼ 8 mice per group), respectively. The nuclei were counterstained with 4’,6-diamidino-2-phenylindole (DAPI;
blue). Scale bars, 500 mm (a), 50mm (c,d) and 1 mm (b). Asterisks indicate the lumen. Dashed lines encircle atherosclerotic lesions. The data are
represented as the mean±s.e.m. of the indicated number (n) of repeats. *Po0.05 and **Po0.01 by Student’s t-test.
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Figure 4 | Expression of miR-103 in ECs during atherosclerosis. (a,b) The expression levels of miR-103, miR-301b, miR-433 and miR-652 (a; n¼ 5 per
group) and their enrichment in AGO2-IPs of human ECs (b). The results of b are expressed as the fold enrichment of miRNAs in AGO2-IP samples
compared with control IgG-IP samples. Results of one representative experiment are shown in b. (c) Quantitative RT–PCR analyses of the expression levels
of miR-103, miR-301b, miR-433 and miR-652 in HAECs with and without TNF-a stimulation (n¼ 3–4 per group). (d) MiRNA expression level in HAECs
treated with vehicle or the NF-kB-inhibitor BAY11-7085 (n¼4–5 per group). (e) Expression levels of miR-103 in HAECs treated with PBS, native low-
density lipoprotein (nLDL) or mildly oxidized-low-density lipoprotein (moxLDL; n¼4 per group). (f) Combined in situ PCR detection of miR-103 and
immunostaining of the endothelial marker CD31 in carotid sections from EC-DicerWT and EC-Dicerflox mice fed a HFD for 4 weeks. Representative images
of three independent experiments are shown. (g) Endothelial miR-103 expression in human atherosclerotic plaques determined by in situ PCR and
immunostaining of von Willebrand factor (vWF). (h) Movat’s pentachrome staining of a human atherosclerotic plaque section located adjacent to that used
for the in situ detection of miR-103. The region of the plaque used for miR-103 expression analysis is indicated. Scale bars, 12mm (f), 25mm (g) and 500mm
(h). Asterisks indicate the lumen. The data are represented as the mean±s.e.m. of the indicated number (n) of repeats. *Po0.05, **Po0.01 and
***Po0.001 by Student’s t-test and one-way analysis of variance.
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and MYB expression46,47. Overexpression and silencing of KLF4
in HAECs increased and reduced the expression of c-MYB,
respectively, whereas the expression of TCF7 mRNA was not
affected (Supplementary Figs 7 and 8). Accordingly, knockout of
Dicer in ECs resulted in c-MYB expression in ECs covering aortic
root lesions, which was not detectable in ECs from EC-DicerWT
mice by dual immunostaining of c-MYB and vWF



















































































































































































































































































































Figure 5 | Effects of miR-103 on chemokine expression in ECs and monocyte adhesion. (a) Chemokine mRNA expression in HAECs treated with Dicer-
specific LNA-GapmeRs or control LNA-GapmeRs with (right) or without (left) miR-103-mimic treatment (n¼4–6 per group). (b,c) Quantitative RT–PCR
analyses of miR-103 (b) and chemokine mRNA (c) expression levels in HAECs (n¼ 5–6 per group) treated with LNA-inhibitors of miR-103 or non-targeting
LNA-oligonucleotides. (d) ELISA of CXCL1 protein expression in HAEC lysates (n¼ 3–4 per group) with and without miR-103 inhibition. (e) Flow chamber
assays to determine monocyte adhesion to HAECs treated with LNA-inhibitors of miR-103 or control oligonucleotides (n¼ 3 per group). (f,g) The
expression of miR-103 (f) or chemokine mRNAs (g) in HAECs treated with miR-103-specific or negative control mimics (n¼ 3–4 per group). (h) Adhesion
of monocytes to HAECs treated with miR-103-mimics or control oligonucleotides under flow conditions. Monocytic cells were pretreated with or without an
antibody to block CXCR2 or non-targeting control IgG (n¼ 3 per group). The data are represented as the mean±s.e.m. of the indicated number (n) of
repeats. *Po0.05, **Po0.01 and ***Po0.001 by Student’s t-test (b–d) and one-way analysis of variance (a,e).
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loss of Dicer upregulates the expression of KLF4-regulated genes
in ECs, such as c-MYB.
Although deficiency of endothelial Dicer preferentially
regulated KLF4-dependent genes, KLF4 mRNA expression levels
in the aortic wall were not different between EC-Dicerflox and
EC-DicerWT mice (Fig. 6e). However, the number of
KLF4-expressing arterial ECs was increased in EC-Dicerflox
























































































































































































Figure 6 | Effect of endothelial Dicer deletion on arterial gene expression. (a) Heat map of genes differentially expressed in the aortas of EC-Dicerflox
mice compared with EC-DicerWT mice (n¼ 2 mice per group; Po0.05; fold change cutoff¼ 1.2) after 12 weeks HFD feeding. (b) Quantitative RT–PCR
analyses of the c-Myb, Tcf7, Lef1, Dkk2 and Sox17 expression levels in the aortas of EC-DicerWT and EC-Dicerflox mice after 12 weeks HFD feeding (n¼4–7
mice per group). (c,d) Significant enriched biological processes (c) and signalling pathways (d) among the genes differentially regulated in EC-Dicerflox
mice as compared with EC-DicerWT mice using Ingenuity Pathway Analysis software. (e) Quantitative RT–PCR analyses of Klf4 mRNA expression in the
aortas of EC-DicerWT and EC-Dicerflox mice after 12 weeks of HFD feeding (n¼4 mice per group). (f) KLF4þ ECs in aortic root sections of EC-DicerWT and
EC-Dicerflox mice identified by immunostaining of KLF4 and the endothelial marker CD31. The arrows indicate ECs with nuclear KLF4 staining. The nuclei
were counterstained with 4’,6-diamidino-2-phenylindole (DAPI). Representative images are shown (n¼ 3–4 mice per group). Scale bar, 25 mm. The data
are represented as the mean±s.e.m. of the indicated number (n) of repeats. *Po0.05; **Po0.01 by Student’s t-test.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms10521
8 NATURE COMMUNICATIONS | 7:10521 | DOI: 10.1038/ncomms10521 | www.nature.com/naturecommunications
translational inhibition of KLF4 expression by miR-103. These
results suggest that activation of the KLF4 pathway in ECs
contributes to the atheroprotective effect of endothelial Dicer
deficiency by reducing arterial inflammation and increasing
endothelial differentiation.
miR-103 induces endothelial inflammation by targeting KLF4.
Notably, miR-103 can directly target the KLF4 mRNA by
binding to a conserved site in its 30 untranslated region
(UTR; Supplementary Fig. 10)48. Overexpressing a mutant
GW182 protein in murine (Fig. 7a) and human ECs (Fig. 7b)
enabled the locking of miRNAs and their targets in the RISC49.
MiR-103-mimic treatment in these cells enriched KLF4 mRNA
but not c-MYB mRNA in the GW182-IPs, demonstrating that
miR-103 targets KLF4, but not c-MYB mRNA in ECs (Fig. 7a,b).
Moreover, treatment of HAECs with LNA inhibitors of miR-103
increased KLF4 protein expression (Fig. 7c) but did not affect
KLF4 mRNA levels (Fig. 7d). By contrast, the expression of KLF2
protein was not affected by treatment of HAECs with LNA
inhibitors of miR-103 (Supplementary Fig. 11). Taken together,
these results suggest that reduced endothelial miR-103 expression
due to Dicer deficiency results in increased KLF4 protein
expression in atherosclerotic endothelium.
Silencing of KLF4 in HAECs upregulated the expression level
of miR-103 (Fig. 7e), as well as those of the CXCL1, CX3CL1 and
CCL2 mRNAs in both the presence and absence of miR-103
inhibition (Fig. 7f). Conversely, overexpression of KLF4
downregulated the expression levels of miR-103 (Fig. 7g) and
the CXCL1, CX3CL1 and CCL2 mRNAs (Fig. 7h) in HAECs, and
treatment with miR-103 mimics prevented the suppression of
chemokine expression by KLF4 (Fig. 7h). These data suggest that
KLF4 affects chemokine expression downstream of miR-103, but
may also act upstream of this miRNA in a negative feedback loop.
TNF-a stimulation and blockage of NF-kB reduced and increased
the expression of KLF4, respectively (Supplementary Fig. 12).
Moreover, inhibition of the interaction between miR-103 and its
binding site in the 30UTR of KLF4 using LNA-modified target site
blockers (KLF4-TSBs) reduced the expression levels of chemokine
mRNAs (Fig. 7i) and diminished monocyte adhesion (Fig. 7j),
demonstrating that miR-103 regulates the adhesive properties of
ECs by targeting KLF4. Overall, these results indicate that
miR-103 induces chemokine expression in ECs by translational
repression of the anti-inflammatory transcription factor KLF4.
Targeting of KLF4 by miR-103 promotes atherosclerosis. To
study the effect of the interaction between miR-103 and KLF4 on
atherosclerosis, Apoe–/– mice were treated with KLF4-TSBs or
control LNA-modified olignonucleotides during the last 4 weeks
of an 8-week HFD feeding programme. Increased endothelial
expression of KLF4 in Apoe–/– mice treated with KLF4-TSBs was
detected by dual immunostaining of KLF4 and vWF (Fig. 8a).
Treatment with KLF4-TSBs reduced the aortic lesion area
(by 53%; Fig. 8b) and the lesional macrophage number (by 30%;
Fig. 8c) compared with the treatment with control oligonucleo-
tides. Moreover, inhibition of the interaction between miR-103
and KLF4 reduced the number of CXCL1-expressing ECs
(Fig. 8d) and downregulated the Cxcl1 mRNA expression in
carotid arteries (Fig. 8e). By contrast, the expression level of Cxcl1
was not affected in other tissues, like the liver, spleen and heart,
following KLF4-TSBs treatment (Fig. 8e). Treatment with
KLF4-TSBs induced endothelial expression of eNOS in aortic root
lesions and the expression of Nos3 in carotid arteries (Fig. 8f,g).
Serum cholesterol levels were similar between control mice
and mice treated with KLF4-TSBs (Supplementary Fig. 13).
Taken together, these findings indicate that miR-103 enhances
atherosclerotic lesion formation by suppressing KLF4.
Discussion
Here, we demonstrate that deficiency of Dicer in the endothelium
of Apoe–/– mice diminishes endothelial inflammation, which
reduces monocyte adhesion to atherosclerosis-prone endothelium
and the development of atherosclerotic lesions. Deletion of Dicer
in ECs primarily decreased the expression of a small subset
of unstable miRNAs, including miR-103, and promoted
KLF4-dependent gene expression. MiR-103 expression was
upregulated by NF-kB and mildly oxidized LDL in human ECs
and increased the expression of CXCL1 by targeting KLF4,
thereby enhancing monocyte adhesion to ECs. Inhibition of the
miR-103-KLF4 interaction reduced atherosclerosis, lesional
macrophage accumulation and endothelial CXCL1 expression
in the arteries of Apoe–/– mice, indicating a proinflammatory and
proatherogenic role of miR-103 by targeting KLF4.
The normal functions of various differentiated cell types, such
as cardiomyocytes, pancreatic beta cells and SMCs, requires Dicer
activity and fully functioning miRNA biogenesis32,33,50. However,
mice with a deletion of the Dicer gene in ECs develop normally,
indicating that permanent Dicer activity is of less importance in
EC homeostasis37. Notably, knockdown of Dicer in ECs
in vitro reduces the expression of CXCL1 and upregulates
endothelial genes, like eNOS and Tie2, indicating that Dicer
promotes inflammatory activation and impairs endothelial
differentiation38,51. ECs at arterial bifurcations are primed
by disturbed flow for inflammatory activation in response to
hyperlipidemic stress, which results in NF-kB-dependent
upregulation of CXCL1 and atherogenic monocyte adhesion8,15.
Accordingly, we found that endothelial Dicer deficiency
downregulates CXCL1 in murine arteries and reduces the
adhesion of monocytes to the endothelium during the early
stage of atherosclerosis. In line with its effect on monocyte
adhesion, deficiency of Dicer in ECs reduced the development of
atherosclerosis and the accumulation of lesional macrophages,
suggesting that the generation of miRNAs in ECs during
atherosclerosis promotes lesion formation by increasing
CXCL1-dependent monocyte adhesion. The detrimental role of
endothelial Dicer during atherogenesis may be due to the key role
of miRNAs in the maladaptive response of ECs to disturbed flow.
The miRNA expression profile in ECs exposed to disturbed blood
flow at arterial bifurcations differs substantially from that in ECs
at unbranched arterial segments42 and is characterized by
downregulation of atheroprotective (such as miR-126-5p)52 and
upregulation of pro-atherogenic miRNAs (such as miR-92a)41.
Moreover, ECs at arterial bifurcations proliferate more frequently
than quiescent ECs at unbranched segments52. In contrast to
proliferating cells, the majority of miRNAs in quiescent cells is
stable (persistence of miRNAs up to 2 months following
Dicer ablation in neurons in vivo have been reported)53,
stored in Argonaut complexes and functionally silent probably
due to their sequestration by polysomes29,54–56. Therefore,
reduced endothelial miRNA biogenesis at predilection sites of
atherosclerosis may cause the protective effects of endothelial
Dicer deficiency on lesion formation.
Although miRNAs are generally stable, a small subset of
miRNAs that associates with Argonaut proteins demonstrates fast
turnover rates in a highly dynamic and cell type-specific
manner28,29,57. After silencing of Dicer in ECs, let-7 family
miRNAs, miR-103, miR-221 and miR-27b have a higher turnover
rate than miR-126-3p, miR-21, miR-23a and miR-26a39. We
found that the expression levels of four miRNAs, including
miR-103, were highly dependent on endothelial Dicer activity.
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Hence, downregulation of unstable miRNAs, like miR-103,
following Dicer deletion may limit monocyte adhesion and
atherosclerosis in mice. MiR-103 has a key role in regulating
insulin sensitivity in adipocytes by targeting caveolin-1, and in
cancer cell growth and metastasis by repressing different targets,
including KLF4 (refs 48,58,59). MiR-103 is one of the most highly
expressed miRNA in ECs cultured under static conditions and
downregulated by high-shear stress38,60. In vivo, miR-103 is
upregulated at predilection sites for the development of
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endothelial NF-kB activation42. The results presented here show
that NF-kB activation upregulates miR-103 and thereby promotes
the expression of chemokines, such as CXCL1, CCL2 and
CX3CL1. MiR-103 increased CXCL1-dependent monocyte
adhesion and rescued the decreased chemokine expression
caused by knockdown of Dicer in ECs, indicating that reduced
endothelial miR-103 levels limit monocyte adhesion
and atherosclerosis in EC-Dicerflox mice by downregulating
CXCL1.
The reduced endothelial inflammation in atherosclerotic
arteries of EC-Dicerflox mice was associated with enhanced
KLF4 activity. Although KLF4 is closely related to KLF2, only
30% of the KLF4-regulated genes in ECs are also controlled by
KLF2, indicating non-redundant roles of KLF2 and KLF4 in
endothelial function46. For example, KLF4 but not KLF2
upregulates Cdh5 and Claudin-5 by direct interaction with their
promoter and thus reduces endothelial permeability61–63. By
contrast, both KLF4 and KLF2 attenuate endothelial
inflammation by inhibiting NF-kB activation through
competitive binding to the p300 coactivator2. An
atheroprotective role of endothelial KLF4 was demonstrated by
gain-an-loss-function studies in mice64. The expression of KLF2
and KLF4 is transcriptionally upregulated by the MEK5/Erk5/
MEF2 signalling pathway and posttranscriptionally silenced by
disturbed flow-induced miR-92a3,65. In accordance with previous
reports in cancer cells, we found that miR-103 represses the
translation of KLF4 mRNA by direct interaction with a conserved
binding site in its 30UTR, which results in NF-kB-mediated
upregulation of CXCL1 in ECs48. Hence, miR-103 might act as a
molecular switch for the inflammatory activation of arterial ECs
by fine-tuning the functional antagonism between KLF4 and
NF-kB. The findings that inhibition of the interaction between
miR-103 and KLF4 reduced atherosclerosis and increased
endothelial KLF4 expression in Apoe–/– mice demonstrates a
proatherogenic role of this interaction and suggests that
derepression of KLF4 due to downregulation of miR-103
contributes to the atheroprotective effect of Dicer deficiency
in ECs.
In conclusion, deficiency of Dicer in the endothelium of
Apoe–/– mice reduced monocyte adhesion to the early athero-
sclerotic endothelium by downregulating CXCL1, and thereby
diminished lesion formation. Thus, endothelial Dicer activity
at arterial sites predisposed to atherosclerosis may play a
pro-atherogenic role by generating proinflammatory miRNAs.
This effect of Dicer is attributable to reduced endothelial miR-103
expression and the subsequent restoration of KLF4 expression.
Moreover, selective inhibition of the targeting of KLF4 by
miR-103 using antisense oligonucleotides may represent a novel
approach to treat atherosclerosis.
Methods
Animal models. Cdh5-CreERT2 mice (kindly provided by Dr Iruela-Arispe,
UCLA, Los Angeles, CA, USA) were crossed with Dicer1flox/flox/Apoe–/–
mice (Jackson Laboratory) to obtain Cdh5-CreERT2Dicer1WT/flox/Apoe–/–
mice66,67. Cdh5-CreERT2Dicer1flox/flox/Apoe–/– (EC-Dicerflox) and Cdh5-
CreERT2Dicer1WT/WT/Apoe–/– (EC-DicerWT) littermates were used for
experiments. Cre recombinase activity was induced by intraperitoneal injection
of the mice with TMX (2 mg per 20 g body weight; Sigma-Aldrich) dissolved in
neutral oil (Migyol; Sasol) for 5 consecutive days. Deletion of the conditional
Dicer allele after TMX injection was verified in the aortas of EC-Dicerflox
mice by PCR67. One week after the last TMX injection, 6- to 8-week-old
female mice were fed a HFD consisting of 21% crude fat, 0.15% cholesterol
and 19.5% casein (Altromin, Lage, Germany) for the indicated time points. For
immunohistochemistry, the aortas and carotid arteries were harvested after in situ
perfusion fixation with 4% paraformaldehyde (Carl Roth) or PAXgene (Qiagen).
For purification of mRNAs or miRNAs, the arteries were perfused with RNAlater
(Life Technologies). All animal experiments were reviewed and approved by the
local authorities (State Agency for Nature, Environment and Consumer Protection
of North Rhein-Westphalia and District Government of Upper Bavaria) in
accordance with the German animal protection laws.
Histology and immunostaining. Thoracoabdominal aortas were prepared en face
and stained with Oil Red O stain. The Oil Red O-positive area was quantified from
digital images of the aorta using image analysis software (ImageJ). Serial sections
(5 mm thick) from carotid arteries and aortic roots were stained with Movat’s
pentachrome or Elastic van Gieson stain. A bright-field microscope (Leica
DM6000B; Leica Microsystems) connected to a CCD camera (Leica DFC365FX)
was used to obtain the images. The lesion area was quantified using planimetry
(Leica LAS software). Immunostaining of CXCL1 (1:25; rabbit polyclonal antibody,
PeproTech), macrophage-specific Mac2 (MAC2; 1:400; clone M3/38, Cedarlane),
a-smooth muscle actin (1:200; clone 1A4, Dako), CD31 (1:75; goat polyclonal
antibody, Santa Cruz Biotechnology), vWF (1:1,000; rabbit polyclonal antibody,
Abcam), KLF4 (1:200; rabbit polyclonal antibody, Abcam), eNOS (1:100; purified
mouse antibody, BD Bioscience) and c-MYB (1:300, rabbit polyclonal antibody,
Hölzel Diagnostika Handels GmbH) was performed in carotid arteries or aortic
root sections. The staining of KLF4 and CD31 was performed separately on
adjacent sections. Cell nuclei were counterstained with 40 ,6-diamidino-2-pheny-
lindole (Vectashield, Vector Laboratories). The positively stained area or the
number of positive cells was normalized to the lesion area or lesional cell number,
respectively, using ImageJ. Non-specific primary antibodies were used as negative
controls (Santa Cruz Biotechnology). The background of the negative control defined
the threshold. The analysis of the stainings was performed in blinded manner.
Human carotid lesion samples. Human atherosclerotic lesion samples were
obtained during carotid endarterectomy and fixed with 4% paraformaldehyde
(Carl Roth). The Ethics Committee of the Medical Faculty at RWTH Aachen
University approved the study protocol for the collection of human atherosclerotic
plaque specimens and all participants gave their written informed consent.
Blood chemistry. Serum cholesterol levels were measured by dry chemistry using
a Vitros 250 Analyzer (Ortho Clinical 10 Diagnostics).
Ex vivo perfusion of carotid arteries. The left carotid arteries were isolated from
EC-Dicerflox and EC-DicerWT mice after 4 weeks of HFD feeding and were
mounted onto a microscopic stage. Monocytic Mono Mac6 cells (MM6; 106 cells
per ml; Leibniz Institute DSMZ-German Collection of Microorganisms and
Cell Cultures, Braunschweig, Germany) labelled with calcein AM (1 mM; Life
Technologies), were perfused at a flow rate of 4 ml min 1 and monocytic cell
adhesion was recorded using stroboscopic epifluorescence illumination15.
Figure 7 | miR-103 promotes inflammatory activation of ECs by targeting KLF4. (a,b) Enrichment of Klf4 and c-Myb transcripts in the miRNA-induced
silencing complex (RISC) of mouse aortic ECs (a) and human aortic ECs (HAECs, b) treated with miR-103-mimics as determined by GW182-IP. The results
are expressed as the fold enrichment of the mRNAs in GW182-IP samples compared with the input samples. Results of two independent experiments are
shown. ND indicates not detected. (c) Immunoblot analyses of KLF4 protein expression in HAECs treated with LNA-inhibitors of miR-103, non-targeting
control LNA-oligonucleotides or premade KLF4 mRNA (n¼ 3–4 per group). The KLF4 protein levels were normalized to those of GAPDH. Full scans of
western blots are provided in Supplementary Fig. 14. (d) KLF4 mRNA levels in HAECs treated with LNA-inhibitors of miR-103 or control LNA-
oligonucleotides (n¼4–5 per group). (e) MiR-103 expression after silencing KLF4 using siRNA (siKLF4) in HAECs. A non-targeting siRNA (siNTC) was
used in the control group (n¼4–5 per group). (f) The expression of CXCL1, CX3CL1 and CCL2 after silencing KLF4 (siKLF4) in HAECs treated with (right) or
without (left) LNA-inhibitors of miR-103 (n¼4–5 per group). siNTCs were used in the control group. (g,h) The effect of transfection with GFP mRNAs
(Ctrl) or premade KLF4 mRNAs on miR-103 (g) and chemokine expression (h) in HAECs treated with (h, right) or without (g; h, left) miR-103-mimics
(n¼ 3–5 per group). (i) Expression of CXCL1, CX3CL1 and CCL2 in HAECs treated with LNA-oligonucleotides (KLF4-target site blockers; KLF4-TSBs)
designed to inhibit the interaction between miR-103 and the 30UTR of KLF4 (n¼6 per group). Non-targeting LNA-oligonucleotides were used in the control
group. (j) Flow chamber assays to determine monocyte adhesion to HAECs treated with KLF4-TSBs or non-targeting oligonucleotides (n¼4 per group).
The data are represented as the mean±s.e.m. of the indicated number (n) of repeats. *Po0.05, ** Po0.01 and *** Po0.001 by Student’s t-test
(a,b,d–j) and one-way analysis of variance (c).
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In vivo target site blocker treatment. Following 4 weeks of HFD feeding, Apoe–/–
mice were randomized to the different experimental groups and injected once
weekly via the tail vein with KLF4 LNA-target site blocker oligonucleotides
(50-GTATGCAGCAGTTGG-30) or control LNA-target site blocker oligonucleo-
tides (50-GCTCCCTTCAATCCAA-30 ; 0.4 mg per 20 kg; miRCURY LNA Target
Site Blocker, in vivo use; Exiqon). During the injection period, mice were fed with a
HFD. The tissues were harvested 1 week after the last injection.
MiRNA real-time PCR array. After reverse transcription and pre-amplification of
total RNA using the Megaplex RT & Preamp Rodent Pool Set (Life Technologies),
the samples were loaded onto preconfigured 384-well microfluidic TaqMan Array
MicroRNA Cards for real-time PCR (RT–PCR) analyses of 641 mouse miRNAs,
using the 7900HT Real-Time PCR System (all from Life Technologies). Data
analysis was performed using StatMiner software (Integromics) along with multiple
internal control genes and the cycle threshold (CT) method. After 4 and 12 weeks
HFD feeding, a total of 428 and 458 miRNAs, respectively, were detected according
to the detection limit (defined as a CT¼ 40) of the individual assays.
Global gene expression analysis. Global gene expression analysis was performed
using Agilent 8 60 K SurePrint G3 Mouse Gene Expression in combination
with a one-colour-based hybridization protocol (IMGM Laboratories GmbH).
Fluorescent signals on the microarrays were detected using the Agilent DNA
Microarray Scanner (Agilent Technologies Germany GmbH). Flagged genes were















































































































































































Figure 8 | Inhibition of the interaction between miR-103 and KLF4 limits atherosclerosis. (a) Immunostaining of KLF4 and von Willebrand factor (vWF)
in aortic root sections of Apoe–/– mice treated with KLF4-TSBs or non-targeting LNA-oligonucleotides (control). Representative images are shown.
Atherosclerosis (b) quantified in Oil red O-stained, en face prepared aortas and the lesional macrophage cell number (c) determined by MAC2
immunostaining in aortic root lesions from Apoe–/– mice treated with KLF4-TSBs or control oligonucleotides (n¼4–6 mice per group). (d) Dual
immunostaining of CXCL1 and vWF in aortic root sections of Apoe–/– mice treated with KLF4-TSBs or control oligonucleotides. (e) The expression levels of
Cxcl1 in the carotid, liver, spleen and heart of KLF4-TSB-treated Apoe–/– mice compared with control mice (n¼4–7 mice per group). (f) Dual
immunostaining of eNOS and vWF in aortic root sections of Apoe–/– mice treated with KLF4-TSBs or control oligonucleotides. (g) Nos3 mRNA expression in
the carotid arteries of KLF4-TSB-treated Apoe–/– mice compared with control mice (n¼ 5–6 mice per group). The nuclei were counterstained with 4’,6-
diamidino-2-phenylindole (DAPI). Asterisks indicate the lumen. Representative images of three independent experiments are shown. Scale bars, 10mm (f),
25mm (a,d), 50mm (c) and 1 mm (b). The data are represented as the mean±s.e.m. of the indicated number (n) of repeats. *Po0.05 and **Po0.01 by
Student’s t-test.
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using robust multi-array average, and significant differential expression was
determined by moderated t-test (Limma) using a P-value cutoff of 0.05 and a fold
change cutoff of 1.2 (GeneSpring GX Software, Agilent). Differentially regulated
genes were analysed by Ingenuity Pathway Analysis (Qiagen). The Fisher’s exact
t-test was selected for the function and pathway analysis.
Preparation of moxLDL. Human native low-density lipoprotein (nLDL;
1 mg ml 1, Calbiochem, Millipore) was incubated with 5 mM CuSO4 at 37 C
for 4 h to prepare mildly oxidized-low-density lipoprotein (moxLDL). The LDL
oxidation was stopped by adding 10 mM EDTA and the LDL was passed through
PD-10 desalting column (GE Healthcare). To prepare nLDL for experimental use
as a negative control, all the above steps were performed except the addition of
CuSO4. The moxLDL and nLDL were used within 14 days after preparation and
stored at 4 C.
Cell culture. HAEC (Cat. # C-12271; PromoCell), umbilical vein ECs (HUVEC;
Cat. # CC-2517; Lonza) and mouse aortic ECs (Pelobiotech) were cultured in
collagen-coated dishes (Millipore) using EC-growth medium (PromoCell). HAECs
were stimulated for 6 h with TNF-a (10 ng ml 1; R&D Systems), nLDL
(50 mg ml 1; Calbiochem, Millipore) or moxLDL (50 mg ml 1, Calbiochem,
Millipore). HAECs were incubated for 30 min with 5 mM BAY11-7085 (Millipore)
to block NF-kB activation. Subsequently, the medium was replaced and RNA was
isolated after 24 h. HAECs were cultured in collagen-coated perfusion chambers
(m-Slides VI0.4, ibidi GmbH) and exposed to high-shear stress (15 dyne cm 2)
or low-shear stress (4 dyne cm 2) for 48 h generated by perfusion with medium
(ibidi Pump System, ibidi GmbH).
Gram-negative endotoxin levels were tested in the medium of HAECs und
HUVECs using the LAL Chromogenic Endotoxin Quantitation Kit (Thermo
Scientific). The endotoxin concentration was consistently less than 0.1 Endotoxin
Units (EU)/ml.
MM6 cells (Mono Mac 6; Leibniz Institute DSMZ-German Collection of
Microorganisms and Cell Cultures) were cultured in RPMI medium (with
L-Glutamine; GE Healthcare Life Sciences) containing 10% FBS, OPI media
supplement (1 mM oxaloacetate, 0.45 mM pyruvate, 0.2 U ml 1 insulin;
Sigma-Aldrich), 1 MEM non-essential amino acids (Life Technologies),
2.5 mg ml 1 Plasmocin (InvivoGen), 100 mg ml 1 streptomycin and 100 U ml 1
penicillin (Life Technologies).
To isolate ECs, the periadventitial fat and connective tissue was removed from
the aortas of EC-DicerWT and EC-Dicerflox mice 2 weeks after TMX injection. The
tissue was cut into 1–2 mm2 sections, which were cultured in endothelial growth
medium (PromoCell) for 7 days to allow the outgrowth of ECs. Subconfluent ECs
of passage 3–5 were used for experiments. The EC phenotype was confirmed by
lectin staining (Lycopersicon esculentum; Sigma)15.
Myeloid cells were isolated from the blood of EC-DicerWT and EC-Dicerflox
mice 4 weeks after TMX injection and HFD feeding by magnetic cell sorting using
CD11bþ microbeads (MACS Miltenyi Biotec GmbH).
Treatment of HAECs. Lipofectamine RNAiMAX (Life Technologies) was used
to transfect HAECs with a LNA-miR-103 inhibitor (50 nM, miRCURY LNA
microRNA Inhibitors; Exiqon), a miR-103 mimic (15 nM, mirVana mimics; Life
Technologies), Dicer GapmeRs (10 nM, LNA GapmeRs; Exiqon), miR-103-KLF4
target site blockers (50 nM miRCURY LNA microRNA Target Site Blockers;
Exiqon), premade KLF4 mRNA (2mg, mRNAExpress Human KLF4 Transcript;
BioCat GmbH) or scrambled controls. Total RNA was isolated after 24 or 48 h
using the RNeasy Mini Kit (Qiagen) or mirVana Isolation Kit (Life Technologies).
HAECs were transfected with a small interfering RNA (siRNA) against KLF4 or a
non-targeting siRNA (1mM Accell siRNA in Accell Delivery Cell Culture Medium;
Thermo Scientific) for 72 h. Additional treatment with the LNA-miR-103 inhibitor
was performed as described above.
Quantitative real-time PCR. Total RNA was isolated from carotid arteries, aortas
or cultured ECs using the mirVana miRNA Isolation Kit (Life Technologies), the
RNeasy Mini Kit (Qiagen) or NucleoSpin microRNA Kit (Macherey-Nagel
GmbH & Co. KG) and reverse-transcribed with a TaqMan microRNA reverse
transcription kit or a high-capacity cDNA reverse transcription kit (both from Life
Technologies). MiRNA qRT-PCR was performed using TaqMan microRNA assays
and TaqMan Universal PCR Master Mix (both from Life Technologies). qRT–PCR
assays for mRNAs were performed either with TaqMan gene expression assays and
TaqMan Universal PCR Master Mix (both from Life Technologies) or with
gene-specific primers (Sigma-Aldrich; Supplementary Table 3) and a SYBR Green
Master Mix (Thermo Scientific). All qRT–PCR experiments were run on a 7900HT
real-time PCR system (Life Technologies). The data were normalized to single or
multiple reference genes (sno-135, RNU44 and U6 for miRNAs; GAPDH and B2M
for mRNAs) and scaled to the sample with of the lowest expression using Qba-
sePLUS software (Biogazelle NV).
In situ reverse transcriptase PCR. Sections (5mm thick) of carotid arteries and
aortic roots were treated with DNase (Roche) for 15–17 h at 37 C. One-step
reverse transcriptase in situ PCR was performed using gene-specific Taq in situ
primers (Sigma-Aldrich; Supplementary Table 3), SuperScript One-Step RT–PCR
with PlatinumTaq (Life Technologies), and digoxigenin-11-dUTPs (Roche)68.
After two washes with saline-sodium citrate buffer buffer and blocking of biotin/
avidin-binding sites (Blocking Kit; Vector Laboratories), the sections were
incubated with horseradish peroxidase-conjugated anti-digoxigenin sheep F’ab
fragments (Roche) for 1 h at 37 C. The probes were visualized using a tyramide-
based amplification system (TSA Plus Biotin; Perkin Elmer) and DyLight 549-
labelled streptavidin (Kirkegaard & Perry Laboratories)52.
Argonaute 2 immunoprecipitation. ECs were harvested and washed in ice-cold
phosphate-buffered saline (GE Healthcare Life Sciences), and then incubated in
lysis buffer containing 400 mM vanadyl ribonucleoside complexes (New England
Biolabs) and protease inhibitors (Complete Protease Inhibitor Cocktail Tablets;
Roche).26 The cell lysates were centrifuged and the input RNA was extracted from
the supernatant using TRIzol reagent (Life Technologies). A human monoclonal
AGO2 Ab (5mg per 1,000 ml; clone 2E12-1C9; Abnova) or control IgG (5mg per
1,000 ml; Millipore) was pre-incubated with protein A/G-conjugated magnetic
beads (Millipore), and then incubated with the cell extract for 7 h at 4 C. The
precipitate was immobilized with a magnetic separator (Millipore). RNA was
isolated from the precipitate using TRIzol reagent, reverse-transcribed using a
high-capacity cDNA reverse transcription kit (Life Technologies), and amplified
with gene-specific primers (Supplementary Table 3) and SYBR Green PCR
Master Mix (Thermo Scientific). The fold enrichment of target genes in
AGO2-immunoprecipitates (AGO2-IPs) over IgG-immunoprecipitates
(IgG-IPs) was calculated as follows: DCTAGO2-IP¼CTinputCTAGO2-IP,
DCTIgG-IP¼CTinputCTIgG-IP, DDCT¼DCTAGO2-IPDCTIgG-IP; and fold
enrichment¼ 2DDCT.
MiRNA target identification and quantification system (MirTrap). HAECs and
mouse aortic ECs were co-transfected with miR-103-mimics and pMirTrap Vector
using the Xfect MicroRNA Transfection Reagent in combination with Xfect
Polymer for 24 h (all from Clontech). The pMirTrap Vector expressed a
DYKDDDDK-tagged GW182 protein, which enabled locking of the miRNA/
mRNA complex into the RISC49. After 24 h, ECs were harvested and washed in ice-
cold  1 phosphate-buffered saline (GE Healthcare Life Sciences), and then
incubated in lysis buffer (MirTrap System, Clontech) supplemented with protease
inhibitors (Complete Protease Inhibitor Cocktail Tablets; Roche). The cell lysates
were centrifuged and part of the input RNA was extracted from the supernatant
using the NucleoSpin RNA XS Kit (Macherey-Nagel GmbH & Co. KG). Anti-
DYKDDDDK-conjugated magnetic beads were washed twice with lysis/wash buffer
containing 1 mM dithiothreitol, 0.1 U ml 1 RNase inhibitor and protease inhibitors
(Complete Protease Inhibitor Cocktail Tablets; Roche) and blocked for 3 h at 4 C
with 1.25 mg ml 1 tRNA solution and 1.25 mg ml 1 BSA. To immunoprecipitate
the DYKDDDDK-tagged RISC complex, blocked anti-DYKDDDDK beads were
incubated with the cell extract for 2 h at 4 C. Immobilization of the precipitates
and subsequent RNA isolation was performed using the NucleoSpin RNA XS Kit
(Macherey-Nagel GmbH & Co. KG). Reverse transcription of input and IP samples
were performed using a high-capacity cDNA reverse transcription kit (Life
Technologies), followed by the amplification with gene-specific primers
(Supplementary Table 3) using the SYBR Green PCR Master Mix (Thermo
Scientific). The fold enrichment was calculated according to the manufacturer’s
protocol. Efficiency of transfection has been determined by performing a control
transfection using miR-132-mimic, the pMirTrap Vector and the pMirTrap
Control Vector, which express an AcGFP1 fluorescein protein containing a miR-
132 target sequence. The efficient enrichment of AcGFP1 fluorescein protein in the
RISC was confirmed and compared to that of a non-miR-132 target gene, such as
Lef1 mRNA transcript.
Flow adhesion assay. Mono Mac6 cells (MM6; 0.5  106 cells per ml) were
labelled with calcein AM (1mM) and, for some experiments, were treated with an
antibody against C–X–C chemokine receptor type 2 (20mg ml 1, clone 48311) or
an isotype control IgG (20 mg ml 1, clone 20102; both from R&D Systems).
HAECs were cultured in collagen-coated cell culture dishes (35 10 mm2; Becton
Dickinson) and transfected with LNA-miR-103, miR-103 mimic, KLF4 target site
blockers or scrambled controls for 24 h. MM6 cells were resuspended in medium
containing 1 Hank’s Balanced Salt Solution (Life Technologies), 1 M HEPES
(Thermo Scientific) and 0.5% bovine serum albumin, and then perfused in a
parallel plate flow chamber over a confluent monolayer of HAECs at a flow rate of
0.1 ml min 1. Monocytic cell arrest on the endothelial monolayer was visualized
by videomicroscopy at  10 magnifications. After a 2-min observation period,
cells adhering to the HAEC monolayer were counted in at least ten different
microscopic view fields within 8 min.
Enzyme-linked immunosorbent assay. The CXCL1 protein concentration was
determined in HAEC cell lysates with the GRO/MGS ELISA Development Kit
(PeproTech). The absorbances were measured at 450 and 405 nm, respectively, on a
microplate reader (Tecan).
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Western blot analysis. HAECs were lysed in RIPA buffer (Sigma-Aldrich)
including protease inhibitors (Complete Protease Inhibitor Cocktail, Roche).
Cell lysates were resolved on SDS–PAGE gels and then transferred to nitrocellulose
membranes. Proteins were detected using primary antibodies against KLF4
(1:1,000, EPR3550(2)ABC, Abcam), KLF2 (1:75, ab139699, Abcam) and GAPDH
(1:1,000, clone 6C5, Millipore), and horseradish peroxidase (HRP)-conjugated
secondary antibodies (1:1,000, Goat Anti-Mouse IgG HRP Affinity Purified PAb,
R&D Systems; Goat Anti-Rabbit IgG HRP Affinity Purified PAb, Santa Cruz).
Protein bands were visualized using an enhanced chemiluminescence detection
system (ECL Advance, GE Healthcare Life Sciences) and an LAS 3000 Imager (Fuji
Photo Film Co., Ltd.) and were quantified using Multigauge software (Fuji Photo
Film). Intensities of the KLF4 and KLF2 bands were expressed as a percentage of
those of the GAPDH bands.
Statistical analysis. The miRNA real-time PCR array data were analysed using
StatMiner 4.2 software (Integromics) and are presented as mean values. All other
data represent the mean±s.e.m. Student’s t-tests and one-way analysis of variance
followed by the Newman–Keuls post-hoc test were used for statistical comparisons
between groups using Prism 6 software (GraphPad Software Inc.). Sample size was
estimated using StatMate software (GraphPad Software Inc.). Po0.05 was con-
sidered statistically significant.
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Corrigendum: Endothelial Dicer promotes
atherosclerosis and vascular inflammation by
miRNA-103-mediated suppression of KLF4
Petra Hartmann, Zhe Zhou, Lucia Natarelli, Yuanyuan Wei, Maliheh Nazari-Jahantigh, Mengyu Zhu,
Jochen Grommes, Sabine Steffens, Christian Weber & Andreas Schober
Nature Communications 7:10521 doi: 10.1038/ncomms10521 (2016); Published 3 Feb 2016; Updated 7 Jun 2016
This Article contains an error in the dose of LNA-target site blocker oligonucleotides that was administered. In the Methods section,
under the subheading ‘In vivo target site blocker treatment’ the dose ‘0.4 mg per 20 kg’ should read ‘0.4 mg per 20 g’.
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